News 2018-04-24
Porton Pharma Solutions and Codexis Launch Global Partnership
“We are delighted to establish this unique partnership with Porton,” said John Nicols, president and CEO of Codexis. “Given Porton’s significant and fast-growing presence as a leading global CDMO, we will now be able to reach a greater share of the world’s pharmaceutical manufacturing market.”
About Codexis
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.
Codexis Contacts:
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.

News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.